M&A alert. Dr. Wargha Enayati buys controlling stake in Intermedicas

Newsroom 24/02/2017 | 17:42

Dr. Wargha Enayati has purchased a 51 percent stake in Intermedicas, the clinic providing second opinion services.

The whole deal is valued at EUR 400,000 and it includes a capital injection and additional funds for the development of the company.

Commenting on the acquisition, Enayati said that Intermedicas is one of the start-ups that has a lot of development potential alongside the other medical projects in which he has invested.

Under the new shareholding structure, Enayati will hold the majority of the shares, while Ana-Maria Marian will have a 21 percent stake, Sergiu Negut – 15 percent and Dr. Dan Mitrea – 13 percent.

„I am glad that I found here former colleagues from Regina Maria and a management team with which I share common values in terms of the medical services and care to patients,” said the new shareholder of Intermedicas.

Earlier this year, the company has launched the first concierge medicine product on the local market, in partnership with several private healthcare services providers including Monza Hospital and Academica Medical Center.

According to Ana-Maria Marian, over 600 employees have been enrolled in this program up to now.

The deal comes less than one year after Enayati, the founder of Regina Maria clinics group, has taken over Versa Media, a firm providing medical communication and BTL services.

In 2015, Enayati exited Regina Maria, after private equity fund Mid Europa Partners took over the stakes owned by his family and by US investment fund Advent International.

Ovidiu Posirca

BR Magazine | Latest Issue

Download PDF: Business Review Magazine April 2024 Issue

The April 2024 issue of Business Review Magazine is now available in digital format, featuring the main cover story titled “Caring for People and for the Planet”. To download the magazine in
Newsroom | 12/04/2024 | 17:28
Advertisement Advertisement
Close ×

We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

Accept & continue